Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers

Oncotarget

Volumn 7, Issue 28, 2016, Pages 43352-43362

  Yan, Heping ^a   Kapoor, Vaishali ^a   Nguyen, Kim ^a   Akers, Walter J ^b,c   Li, Hua ^a   Scott, Jalen ^a   Laforest, Richard ^b   Rogers, Buck ^a   Thotala, Dinesh ^a,c   Hallahan, Dennis ^a,b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Washington University in St Louis School of Medicine   (United States)

Author keywords

In vivo imaging; Monoclonal antibody; Radiation inducible; Radioimmuno therapy; TIP 1

Indexed keywords

ANTI TAX INTERACTING PROTEIN 1; CHELATING AGENT; FLUOROCHROME; INDIUM 111; MONOCLONAL ANTIBODY; PENTETIC ACID; PROTEIN; RADIOISOTOPE; TIP 1 PROTEIN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INDIUM; SIGNAL PEPTIDE; TAX1BP3 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CANCER CONTROL; CELL SURFACE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CANCER; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DIAGNOSTIC IMAGING; DRUG SCREENING; IMMUNOLOGY; NEOPLASM; NUDE MOUSE; PROCEDURES; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978708706     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9713     Document Type: Article

References (30)

1. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012; 11:311-331
2. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49:493-507
3. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011; 17: 6389-6397
4. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs. 2013; 5:513-517
5. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schroder CP, Gietema JA, Brouwers AH, de Vries EG. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015; 33:1491-1504
6. Wang H, Yan H, Fu A, Han M, Hallahan D, Han Z. TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS One. 2010; 5:e12051
7. Rousset R, Fabre S, Desbois C, Bantignies F, Jalinot P. The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene. 1998; 16:643-654
8. Besser J, Leito JT, van der Meer DL, Bagowski CP. Tip-1 induces filopodia growth and is important for gastrulation movements during zebrafish development. Dev Growth Differ. 2007; 49:205-214
9. Han M, Wang H, Zhang HT, Han Z. The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice. Biochem Biophys Res Commun. 2012; 422:139-145
10. Wang H, Han M, Whetsell W Jr., Wang J, Rich J, Hallahan D, Han Z. Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma. Oncogene. 2014; 33:1558-1569
11. Hariri G, Yan H, Wang H, Han Z, Hallahan DE. Radiationguided drug delivery to mouse models of lung cancer. Clin Cancer Res. 2010; 16:4968-4977
12. Lowery A, Onishko H, Hallahan DE, Han Z. Tumortargeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release. 2011; 150:117-124
13. Zhang J, Yan X, Shi C, Yang X, Guo Y, Tian C, Long J, Shen Y. Structural basis of beta-catenin recognition by Taxinteracting protein-1. J Mol Biol. 2008; 384:255-263
14. Ferraro DJ, Bhave SR, Kotipatruni RP, Hunn JC, Wildman SA, Hong C, Dadey DY, Muhoro LK, Jaboin JJ, Thotala D, Hallahan DE. High-throughput identification of putative receptors for cancer-binding peptides using biopanning and microarray analysis. Integr Biol (Camb). 2013; 5:342-350
15. Reynaud C, Fabre S, Jalinot P. The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element. J Biol Chem. 2000; 275:33962-33968
16. Kanamori M, Sandy P, Marzinotto S, Benetti R, Kai C, Hayashizaki Y, Schneider C, Suzuki H. The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem. 2003; 278:38758-38764
17. Han M, Wang H, Zhang HT, Han Z. Expression of TIP-1 confers radioresistance of malignant glioma cells. PLoS One. 2012; 7:e45402
18. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9:157-173
19. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005; 56:361-369
20. Sampath L, Kwon S, Ke S, Wang W, SchiffR, Mawad ME, Sevick-Muraca EM. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007; 48:1501-1510
21. D'Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, De Raeve H, Muyldermans S, Caveliers V, Devoogdt N, Lahoutte T. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014; 4:708-720
22. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000; 6:3095-3102
23. Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Min CY, Shin SY, Maloney PJ, Larson SM, Reba RC. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. J Nucl Med. 1989; 30:1693-1701
24. Frampas E, Rousseau C, Bodet-Milin C, Barbet J, Chatal JF, Kraeber-Bodere F. Improvement of radioimmunotherapy using pretargeting. Front Oncol. 2013; 3:159
25. Evans-Axelsson S, Timmermand OV, Bjartell A, Strand SE, Elgqvist J. Radioimmunotherapy for Prostate Cancer-Current Status and Future Possibilities. Semin Nucl Med. 2016; 46:165-179
26. Bodet-Milin C, Kraeber-Bodere F, Eugene T, Guerard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Cherel M, Chevallier P. Radioimmunotherapy for Treatment of Acute Leukemia. Semin Nucl Med. 2016; 46:135-146
27. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol. 2015; 6:54
28. Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol. 2014; 110:362-369
29. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287
30. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012; 12:14